Yantai Dongcheng Pharmaceutical GroupLtd Full Year 2024 Earnings: Misses Expectations

Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥2.87b (down 12% from FY 2023).
• Net income: CN¥183.8m (down 12% from FY 2023).
• Profit margin: 6.4% (in line with FY 2023).
• EPS: CN¥0.22 (down from CN¥0.25 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yantai Dongcheng Pharmaceutical GroupLtd Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Yantai Dongcheng Pharmaceutical GroupLtd you should be aware of, and 1 of them is concerning.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.